Email Sign up Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Bladder Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

2018 ASH Annual Meeting

The 2018 American Society of Hematology Annual Meeting & Exposition, held at the San Diego Convention Center in San Diego, California, from December 1-4, 2018.
Triplet Regimen Could Replace Standard of Care for Transplant-Ineligible Myeloma
Triplet Regimen Could Replace Standard of Care for Transplant-Ineligible Myeloma
Jason M. Broderick
Selinexor Combo Sees Activity in Heavily Pretreated Penta-Refractory Myeloma
Selinexor Combo Sees Activity in Heavily Pretreated Penta-Refractory Myeloma
Wayne Kuznar
Consistent OS Benefit Seen Across Patient Subgroups With Quizartinib in AML
Consistent OS Benefit Seen Across Patient Subgroups With Quizartinib in AML
Jason M. Broderick
Risk of Progression Significantly Reduced With Upfront Ibrutinib and Obinutuzumab in CLL/SLL
Risk of Progression Significantly Reduced With Upfront Ibrutinib and Obinutuzumab in CLL/SLL
Gina Columbus
Durable Responses Achieved With Acalabrutinib in MCL
Durable Responses Achieved With Acalabrutinib in MCL
Wayne Kuznar
Early Activity Seen With Anti-BCMA CAR T Cell in Heavily Pretreated Multiple Myeloma
Early Activity Seen With Anti-BCMA CAR T Cell in Heavily Pretreated Multiple Myeloma
Silas Inman
Key Findings Reviewed From ALCYONE Trial in Myeloma
Key Findings Reviewed From ALCYONE Trial in Myeloma
Maria-Victoria Mateos, MD, PhD
Promising Results Seen With Ibrutinib Plus Venetoclax Combo in Relapsed/Refractory CLL
Promising Results Seen With Ibrutinib Plus Venetoclax Combo in Relapsed/Refractory CLL
Wayne Kuznar
Next Page >>
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.